Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 41 clinical trials
Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

The aim of this study is to demonstrate the efficacy of intensified and sequential chemotherapy (Gabrinox) comprising Gembrax regimen (Gemcitabine-Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) in patients with locally advanced pancreatic adenocarcinoma. The study will also demonstrate the feasibility of combining this intensified chemotherapy with MRI-guided …

  • 0 views
  • 27 Jan, 2021
  • 5 locations
PDAC Peripheral and Portal Vein Sampling

This is a research study in which bio-specimens (whole blood, plasma and serum from peripheral circulation and portal vein) will be collected from patients with pancreatic adenocarcinoma for translational research. These samples will be used for (but not limited to) identification and characterisation of blood-borne biomarkers at the genomic and …

pdac
  • 0 views
  • 06 Aug, 2021
  • 2 locations
A Study Evaluating the Safety Pharmacokinetics (PK) and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and

EGFR
bone marrow procedure
growth factor
primary cancer
treatment regimen
  • 49 views
  • 22 Sep, 2021
  • 52 locations
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth of tumor cells, either by

metastasis
gemcitabine
systemic chemotherapy
systemic therapy
pembrolizumab
  • 238 views
  • 24 Sep, 2021
  • 200 locations
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

metastasis
gemcitabine
carcinoma
squamous cell carcinoma
pembrolizumab
  • 1114 views
  • 23 Sep, 2021
  • 1140 locations
Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

This study examines preoperative Erlotinib in patients with operable stage II and IIIA Non-small-cell lung cancer (NSCLC) harboring EGFR mutations.

EGFR
measurable disease
erlotinib
  • 2 views
  • 26 Jan, 2021
  • 1 location
Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC

The objectives of the study is to determine if either temozolomide or erlotinib combined with WBRT and SRS improves survival as compared to WBRT and SRS alone.Ptients with histologically

whole-brain radiotherapy
metastasis
bone scan
seizure
brain tumor
  • 29 views
  • 07 Nov, 2020
  • 1 location
Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy

RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of non-small cell lung

stage iv non-small cell lung cancer
sorafenib
carcinoma in situ
carcinoma
platelet count
  • 2 views
  • 07 Nov, 2020
  • 1 location
A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC

has been receiving treatment with a targeted biological agent such as erlotinib, crizotinib, or other drugs.

metastasis
lymphoma
targeted therapy
epidermal growth factor receptor
growth factor
  • 0 views
  • 16 Feb, 2021
  • 1 location
Neoadjuvant Afatinib Therapy for Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

erlotinib vs chemotherapy (Gemcitabine plus cisplatin) for stage III NSCLC reveal that erlotinib has improved ORR (54%), major pathological response, operation rate, R0 resection and lymph node downstaging

  • 0 views
  • 29 Jan, 2021
  • 1 location